In Devinsky et al., the study leading to FDA approval, the findings pointed to a statistically significant reduction in the median frequency of convulsive seizures per month with CBD at 20 mg/kg per day, reaffirming the potential of this treatment in effectively reducing seizure frequency in patients with DS [23]. Here, OPN1MW is linked to Dravet syndrome.